Calidi Biotherapeutics Inc. (CLDI) - Total Liabilities
Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) has total liabilities worth $5.10 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Calidi Biotherapeutics Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Calidi Biotherapeutics Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Calidi Biotherapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Calidi Biotherapeutics Inc. assets under control.
Calidi Biotherapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Calidi Biotherapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dialight plc
LSE:DIA
|
UK | GBX54.20 Million |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
USA | $141.18 Million |
|
James Fisher and Sons PLC
LSE:FSJ
|
UK | GBX400.20 Million |
|
CDN Maverick Capital Corp.
F:338B
|
Germany | €349.51K |
|
FEEDBACK PLC LS-5
F:GZM0
|
Germany | €400.00K |
|
Traffic Technologies Ltd
AU:TTI
|
Australia | AU$33.99 Million |
|
CPT Global Ltd
AU:CGO
|
Australia | AU$5.43 Million |
|
AMMPOWER CORP.
F:601A
|
Germany | €8.36 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Calidi Biotherapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Calidi Biotherapeutics Inc. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Calidi Biotherapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Calidi Biotherapeutics Inc. (2020–2025)
The table below shows the annual total liabilities of Calidi Biotherapeutics Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.10 Million | -58.26% |
| 2024-12-31 | $12.21 Million | -33.09% |
| 2023-12-31 | $18.25 Million | -65.58% |
| 2022-12-31 | $53.04 Million | +103.97% |
| 2021-12-31 | $26.00 Million | +6.86% |
| 2020-12-31 | $24.33 Million | -- |
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast ca… Read more